Board of Directors
Navigating critical issues with passion, experience and judgment
Mr. Fogarty has served as a Director of Assertio since October 2016. From November 2011 to July 2015, Mr. Fogarty was Chief Executive Officer and a Director of Orchard Brands. From April 2009 until November 2010, Mr. Fogarty was President, Chief Executive Officer and Director of Charming Shoppes Inc. Prior to that he was Managing Director of Alvarez & Marsal, an independent global professional services firm, and from August 1994 served as President and Chief Operating Officer of Lehman Brothers Holdings subsequent to its Chapter 11 bankruptcy filing in April 2009. Prior to that he was President and CEO of American Italian Pasta Company, Chief Financial Officer of Levi Strauss & Co. and served as Senior Vice President and Chief Financial Officer of The Warnaco Group. Mr. Fogarty currently serves as a Director of Darden Restaurants. Mr. Fogarty received a B.A. in economics and computer science from Williams College and an M.B.A. in finance and accounting from the Leonard Stern School of Business at New York University.
Mr. McKee has served as Director of Assertio since March 2017. He served as Chief Operating Officer and Chief Financial Officer at EKR Therapeutics, Inc., a privately held specialty pharmaceutical company from 2010 until EKR was sold to Cornerstone Therapeutics Inc. in 2012. Until March 2010, Mr. McKee served as the Executive Vice President and Chief Financial Officer of Barr Pharmaceuticals, LLC, a subsidiary of Teva Pharmaceutical Industries Limited, a generic pharmaceutical company, and the successor entity to Barr Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical company, which was acquired by Teva. Mr. McKee was also Executive Vice President and Chief Financial Officer of Barr prior to its acquisition by Teva, after having served in positions of increasing responsibility at Barr until its acquisition. Prior to joining Barr, Mr. McKee served as Director of International Operations and Vice President–Finance at Absolute Entertainment, Inc., a private developer and marketer of entertainment software. Mr. McKee previously worked at Gramkow & Carnevale, CPAs and Deloitte & Touche. Mr. McKee serves on the boards of Agile Therapeutics, Inc., a publicly held specialty biopharmaceutical company, Cerulean, Inc., a publicly held clinical-stage, oncology-focused company and Synthetic Genomics Inc., a privately held synthetic biology company. Mr. McKee received a B.A. in business from the University of Notre Dame.
Ms. Dawes has served as a Director of Assertio since April 2008. Since 2003, Ms. Dawes has served as President of Knowledgeable Decisions, LLC, a pharmaceutical consulting firm that she founded. Between 1999 and 2003, Ms. Dawes served as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group. Prior to joining Bayer, she served as Senior Vice President, Global Strategic Marketing for Wyeth, formerly known as American Home Products, where she held responsibility for worldwide strategic marketing. She also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in 1997. Ms. Dawes began her pharmaceutical industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of positions in marketing, serving most recently as Vice President, Marketing of the Pratt Division. Ms. Dawes serves on the board of Repligen Corporation, a biopharmaceutical company.
Ms. Mason has served as a Director of Assertio since February 2019. Ms. Mason, 58, is a former senior executive of Abbott Laboratories, having recently retired as Executive Vice President of Abbott Nutrition. Ms. Mason also served as Executive Vice President, Global Commercial Operations at Abbott and Senior Vice President of Abbott Diabetes Care. Ms. Mason joined Abbott in 1990 and held positions in Abbott’s U.S. pharmaceutical business, including oversight of Abbott’s specialty pharmaceuticals, its diabetes/metabolics and oncology franchises, and managed health care. Ms. Mason also served as Vice President, International Marketing, and Vice President, Latin American Operations, in Abbott’s international pharmaceutical business. Prior to joining Abbott, Ms. Mason worked for Quaker Oats, FMC Corporation, and Commonwealth Edison. Ms. Mason holds a B.S.E. in Industrial Engineering from the University of Michigan and a M.B.A. from the University of Chicago.
Mr. Higgins joined Assertio as President and Chief Executive Officer and Director in March 2017. He brings over 35 years of pharmaceutical and healthcare industry experience. Most recently, he served as a Senior Advisor to Blackstone Healthcare Partners, the dedicated healthcare team of The Blackstone Group, where he focused on product-based healthcare acquisitions. Prior to that, Mr. Higgins served as Chairman of the Board of Management of Bayer HealthCare AG from January 2006 to May 2010 and Chairman of the Bayer HealthCare Executive Committee from July 2004 to May 2010. Prior to joining Bayer HealthCare in 2004, Mr. Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 to 2004. Prior to joining Enzon Pharmaceuticals, Mr. Higgins spent 14 years with Abbott Laboratories, including serving as President of the Pharmaceutical Products Division from 1998 to 2001. He is a past member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Mr. Higgins serves on the boards of Zimmer Biomet, a publicly held medical device company, Nuvelution, and EcoLab, a publicly held water, hygiene and energy technologies and services company. Mr. Higgins received a B.S. in biochemistry from Strathclyde University, Scotland.
Mr. Tyree has served as a Director of Assertio since October 2016. Mr. Tyree is the co-founder and managing partner of Tyree & D’Angelo Partners, a private equity investment firm. Prior to founding Tyree & D’Angelo Partners in 2010, Mr. Tyree was President, Abbott Biotech Ventures, a subsidiary of Abbott Laboratories focused on investments in early-stage pharmaceuticals and biologics. Before that Mr. Tyree held numerous executive positions at Abbott including Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development, Senior Vice President Global Nutrition and Executive Vice President Global Pharmaceuticals. Prior to rejoining Abbott in 1997, Mr. Tyree was the President of SUGEN, Inc. and held management positions at Bristol-Myers Squibb, Pfizer and Abbott. Mr. Tyree serves as a director of Innoviva, Inc. and Chemocentryx. Mr. Tyree received B.S. degrees in psychology and forensic studies and a M.B.A. from Indiana University.
Mr. Staple has served as a Director of Assertio since November 2003. Since March 2008, Mr. Staple has served as Chief Executive Officer and Director of Corium International, Inc., a publicly held biopharmaceutical company. From 2002 to March 2008 he served as Director, and from 2002 to November 2007 as Chief Executive Officer of BioSeek, Inc., a privately held drug discovery company. From 1994 to 2002, Mr. Staple was a member of the senior executive team at ALZA Corporation, where he was most recently Executive Vice President, Chief Administrative Officer and General Counsel. Prior to joining ALZA, Mr. Staple held the position of Vice President, Associate General Counsel for biopharmaceutical company Chiron Corporation. Mr. Staple previously served as Vice President, Associate General Counsel for Cetus Corporation, a biotechnology company. Mr. Staple received a J.D. degree from Stanford Law School and a B.A. degree from Stanford University.
Mr. Galeota has served as a Director of Assertio since April 2019. Mr. Galeota is the President and Chief Executive Officer of Inheris BioPharma, Inc. Most recently, he served as the President and Chief Operating Officer of G&W Laboratories, Inc. from 2016 to 2019. From 1988 to 2016, Mr. Galeota served in many diverse positions at Merck & Co., Inc., where he served most recently as Chief Strategy and Business Development Officer and President, Emerging Businesses. From 2011 to 2014, he served as President, Hospital and Specialty Care at Merck, and from 2009 to 2011, he served as Senior Vice President of Global Human Health Strategy and Business Development. Mr. Galeota started his career in Merck’s commercial organization, where he held various U.S. and global leadership positions and led numerous brands and key product launches across a variety of therapeutic areas. Mr. Galeota currently serves as a director of Melinta Therapeutics, Inc., a publicly held pharmaceutical company. Mr. Galeota holds a B.S. in biology from Villanova University and is a graduate of Harvard Business School’s Advanced Management Program.